Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

Essai clinique

Efficacy and Safety of NasoAid® After Nasal Surgery

NCT : NCT07861061 · RECRUITING

ID NCTNCT07861061
StatutRECRUITING
Date de début2026-08-24
Achèvement2027-07-31
SponsorMaxigen Biotech Inc. (INDUSTRY)
First posted
Last updated

Résumé succinct

The goal of this clinical trial is to evaluate the effectiveness and safety of collagen-based absorbable nasal packing (NasoAid®) after nasal surgery. The main question it aims to answer are: * The hemostasis 2, 12, 24, 48 hours after nasal packing. * The endoscopic nasal assessments scores. * The remnant percentage of nasal packing material. * Patient-reported Visual Analog Scale (VAS) scores for general assessment. * Patient-reported outcomes, including the Sino-Nasal Outcome Test-22 (SNOT-22), Nasal Obstruction Symptom Evaluation (NOSE), and Total Nasal Symptom Score (TNSS). * The incidences of safety indicators. Participants will be randomized into either experiment group or control group, receive nasal packing at Day0, and re-visited on week 1, 2, 4, 8 and 12 after nasal surgery. Researchers will compare if NasoAid® is non-inferiority to NasoPore.

Source officielle

Voir sur ClinicalTrials.gov →

Données issues de l’API ClinicalTrials.gov. Pour connaître le statut le plus récent, consultez la fiche officielle.

↑